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Temporal Resolution of Misfolded Prion Protein Transport,
Accumulation, Glial Activation, and Neuronal Death in the Retinas of
Mice Inoculated with Scrapie
Abstract
Currently, there is a lack of pathological landmarks to describe the progression of prion disease in vivo. Our
goal was to use an experimental model to determine the temporal relationship between the transport of
misfolded prion protein (PrPSc) from the brain to the retina, the accumulation of PrPSc in the retina, the
response of the surrounding retinal tissue, and loss of neurons. Retinal samples from mice inoculated with
RML scrapie were collected at 30, 60, 90, 105, and 120 days post inoculation (dpi) or at the onset of clinical
signs of disease (153 dpi). Retinal homogenates were tested for prion seeding activity. Antibody staining was
used to assess accumulation of PrPSc and the resulting response of retinal tissue. Loss of photoreceptors was
used as a measure of neuronal death. PrPSc seeding activity was first detected in all samples at 60 dpi.
Accumulation of PrPSc and coincident activation of retinal glia were first detected at 90 dpi. Activation of
microglia was first detected at 105 dpi, but neuronal death was not detectable until 120 dpi. Our results
demonstrate that by using the retina we can resolve the temporal separation between several key events in the
pathogenesis of prion disease.
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Currently, there is a lack of pathological landmarks to describe the progression of prion disease in vivo.
Our goal was to use an experimental model to determine the temporal relationship between the
transport of misfolded prion protein (PrPSc) from the brain to the retina, the accumulation of PrPSc in
the retina, the response of the surrounding retinal tissue, and loss of neurons. Retinal samples from
mice inoculated with RML scrapie were collected at 30, 60, 90, 105, and 120 days post inoculation (dpi)
or at the onset of clinical signs of disease (153 dpi). Retinal homogenates were tested for prion seeding
activity. Antibody staining was used to assess accumulation of PrPSc and the resulting response of
retinal tissue. Loss of photoreceptors was used as a measure of neuronal death. PrPSc seeding activity
was ﬁrst detected in all samples at 60 dpi. Accumulation of PrPSc and coincident activation of retinal
glia were ﬁrst detected at 90 dpi. Activation of microglia was ﬁrst detected at 105 dpi, but neuronal
death was not detectable until 120 dpi. Our results demonstrate that by using the retina we can resolve
the temporal separation between several key events in the pathogenesis of prion disease. (Am J Pathol
2016, 186: 2302e2309; http://dx.doi.org/10.1016/j.ajpath.2016.05.018)
Transmissible spongiform encephalopathies (TSEs) are a
family of diseases caused by the accumulation of misfolded
prion protein (PrPSc).1 During progression of TSEs, like
many protein misfolding disorders, transport of misfolded
protein from one central nervous system (CNS) structure
seeds protein misfolding and accumulation in another.2 The
details underlying this series of events that begins with the
arrival of misfolded protein in a CNS structure and ends
with neuronal death in that structure are not well under-
stood. Seeding the brain with an inoculum of misfolded
prion protein induces TSEs; thus, these diseases provide a
unique opportunity to study the transport of PrPSc from one
CNS structure to another.
Currently, there is no treatment for TSEs. Although in silico
and in vitro approaches have been effective at identifying
compounds with therapeutic potential,3e8 development of
effective therapies would be facilitated by a well-described
in vivo model of misfolded protein transport and accumula-
tion, with objective measures of neural degeneration.
The retina is part of the CNS and is affected by numerous
protein misfolding diseases, including Alzheimer disease,9
Parkinson disease,10e12 and numerous TSEs, including
scrapie in sheep,13,14 chronic wasting disease in
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cervids,15e17 bovine spongiform encephalopathy in cat-
tle,18,19 and Creutzfeldt-Jakob disease in humans.20,21 The
retina and associated visual structures provide an excellent
model to study the transport of misfolded proteins from one
CNS structure to another.22
Herein, we report the time course of transport of mis-
folded prion protein to the retina after inoculation into the
brain in a mouse model of scrapie. We describe the temporal
separation between the ﬁrst detection of misfolded prion
protein at 40% of the 153-day incubation period, the accu-
mulation of PrPSc at 60% of the incubation period, the
activation of microglia at 70% of the incubation period, and
the loss of retinal neurons at 80% of the incubation period.
Thus, we provide a well-described in vivo model that can be
used to study the pathogenesis of disease and to assess the
potential effectiveness of therapeutic approaches against the
spread and accumulation of misfolded prion protein.
Materials and Methods
Ethics Statement
The experiments were performed in accordance with the
Guide for the Care and Use of Laboratory Animals.23 The
protocol was approved by the Institutional Animal Care and
Use Committee at the National Animal Disease Center
(protocol number 3985). Sample size was determined statis-
tically using preliminary data from clinically affected animals.
Animals and Tissue Preparation
C57Bl/6 mice, aged 6 to 8 weeks, were inoculated with a brain
homogenate containing mouse-adapted Rocky Mountain
Laboratories (RML) scrapie via intracranial injection into the
right cerebral hemisphere at the level of the temporal bone.
Tissue collection occurred at 30, 60, 90, 105, and 120 days
post inoculation (dpi), along with another group composed of
animals exhibiting clinical signs approximately 155 dpi. For
each time point, there were two groups of age-matched
negative control mice: a mock-inoculated group that was
inoculated with brain homogenate from healthy mice and a
noninoculated group that received no inoculation (ﬁve to six
animals were included in each group). Globes were collected
into Bouin’s ﬁxative for 24 hours and post-ﬁxed in 10%
formalin until processing. Tissues were then embedded in
parafﬁn, divided into sections (4 mm thick), and afﬁxed to
slides for hematoxylin and eosin staining and immunolabeling.
Expression and Puriﬁcation of rPrP Substrate
Recombinant prion protein (rPrP) used in RT-QuIC assay
was expressed and puriﬁed using standard protocol from
previous reports.24,25 Brieﬂy, rPrP composed of the Syrian
hamster residues 90 to 231 in pET vector with N-terminal
histidine sequence was transformed in to Escherichia coli
Rosetta2(DE3) cells. The cultures were grown under
continuous selection with kanamycin and chloramphenicol in
the Lysogeny broth media. The log phase cultures were
scaled up with Overnight Express Autoinduction System 1
for protein induction. Later, the inclusion bodies were iso-
lated from bacterial pellets using BugBuster Master Mix and
were denatured in 8M guanidine hydrochloride. Later, the
rPrP is bound to pre-equilibrated nickel-nitrilotriacetic acid
superﬂow resin for 50 minutes. The beads were packed in
Akta #XK26 column, and rPrP was puriﬁed using nickel-
nitrilotriacetic acid afﬁnity chromatography on a Bio-Rad
Duo ﬂow system in a refrigerated room. On column refold-
ing was performed using gradient dilution of guanidine hy-
drochloride over 5 hours. Pure rPrP was eluded from the
column using imidazole binding with increasing linear
gradient. Chilled dialysis buffer was added to the peak elude
fractions, and dialyzed overnight against three changes of
chilled dialysis buffer (10 mmol/L NaPO4, pH 5.8) after
initial ﬁltration. Protein concentration was determined using
the extension coefﬁcient and ﬁltering through 100-kDa cutoff
ﬁlters before subjecting to RT-QuIC assay. The quality of
rPrP was conﬁrmed by NMR and CD spectral analyses.
RT-QuIC Assay for Retina Samples
The RT-QuIC assay was performed using previously pub-
lished protocols from published reports24,26,27 with slight
modiﬁcations. The reaction mixtures consisted of ﬁnal con-
centrations of 350mmol/LNaCl, 0.1mmol/LEDTA, 10mmol/
L thioﬂavin T, 0.1 mg/mL rPrP, and 0.002% SDS in 1
phosphate-buffered saline. The retina samples from time
course RML scrapie-infected mice were washed twice and
homogenized using repeated pipetting and sonication in a cup
sonicator with two pulses of 30 seconds. The clariﬁed super-
natants were normalized to protein concentration using Brad-
ford protein assay. The reactions consisted of 5 mg of protein
from retina homogenates that were used as seed. We included
mouse brain homogenates (0.5 mg) from clinical RML scrapie
infected mice, mock brain homogenates, and blank (buffer) as
controls. All of the samples were run using a blinded study
design (N.K., S.M., A.K.). The plates were sealed with Nal-
gene Nunc plate sealer and subjected to RT-QuIC assay. The
plates were incubated at 42C in Cytation3 (Biotek,Winooski,
VT) plate reader with alternate cycles of 1-minute shake
(double orbital) and rest. All of the samples were run in qua-
druplicates, and sampleswere judged to be positive as reported
previously.27 Average ﬂuorescence readings of four replicates
plus 10 times SD of negative controls were the criteria for
determining the threshold. Recording of thioﬂavin T ﬂuores-
cence (450 15nmexcitation and480 10nmemission)was
noted every 30minutes, and data analysiswas performed using
Biotek’s Gen5 software version 2.07.17.
Immunohistochemistry
Parafﬁn-embedded tissues were analyzed using immunohis-
tochemistry. After deparafﬁnization and rehydration, tissue
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sections were autoclaved for 20 minutes in an antigen retrieval
solution (DAKO Target Retrieval Solution; Dako Corp.,
Carpinteria, CA). Mouse anti-PrP (6C2; CVI-WUR, Lelystad,
Neth) was diluted 1:2000. Rabbit anti-glial ﬁbrillary acidic
protein (GFAP) (Dako Corp.) was diluted at 1:10,000. Slides
were incubated in primary antibodies 6C2 overnight at 4C
and GFAP for 24 hours at room temperature and 72 hours at
4C. Immunoreactivity was developed using Envisionþ Dual
Link System-horseradish peroxidase (Dako Corp.) with dia-
minobenzidene (Vector Labs, Peterborough, UK), and slides
were counterstained with hematoxylin. Images were captured
using a Nikon DS camera on a Nikon Eclipse 50imicroscope.
For immunoﬂuorescence detection of CD68 immunoreactivity
(1:100; Dako Corp.), slides were incubated with Cy3 conju-
gated AfﬁniPure secondary antibodies (1:300; Jackson
ImmunoResearch, West Grove, PA) for 1.5 hours and coun-
terstained with DAPI (1 mg/mL; Sigma-Aldrich, St. Louis,
MO). Immunoﬂuorescence images were captured using a
commercial upright microscope system (Zeiss AxioPlan 2
Microscope Imaging System; Oberkochen, Germany).
CD68 immunoreactivity was quantiﬁed using ImageJ
analysis software version 1.49v (http://imagej.nih.gov/ij;
NIH, Bethesda, MD), and was expressed as a percentage of
the total image area (outer limitingmembrane to inner limiting
membrane of the central retina) using constant thresholds.
Values at each time point were pooled and analyzed with one-
way analysis of variance and Tukey’s post hoc test using
Prism 6 for Windows (Graph Pad Software, San Diego, CA).
Assessment of Neuronal Loss
Thinning of the outer nuclear layer was measured by counts of
cell bodies spanning the layer. For each cross section, three
counts were made in the central retina and averaged into a
single value for each animal. Datawere analyzedwith one-way
analysis of variance using Dunnett’s multiple comparison test.
Results
Incubation Period
Seventeen C57Bl/6 mice were used to determine the incu-
bation period of mouse-adapted (RML) scrapie. The average
incubation period was 153 dpi, with a SD of 1.4 days. On
the basis of a 153-day incubation period, tissues were
assayed at 19.6% of total incubation (30 dpi), 39.2% of total
incubation (60 dpi), 58.8% of incubation (90 dpi), 68.6% of
incubation (105 dpi), 78.4% of incubation (120 dpi), and
100% of incubation period (clinical illness).
PrPSc Seeding Activity Is Detected in the Retina at
Approximately 40% of Incubation
The real-time quaking induced conversion (RT-QuIC) assay
was used to determine the time course of misfolded prion
protein transport from the brain to the retina. Seeding activity
in the RT-QuIC assay was noted in all replicates (both
biological and technical) of clinical, 120 dpi, 90 dpi, and 60
dpi retina samples but not in retinas from mock inoculated
animals or from 30 dpi inoculated retina samples (Figure 1A).
Seeding activity in retinal samples was comparable to the
RML scrapie infected brain homogenate (Figure 1A). When
data were expressed as amyloid formation rate [the inverse of
the time for the thioﬂavin T ﬂuorescence signals to cross the
threshold (in hours)], it demonstrated that amyloid formation
rate is proportional to the incubation period. That is, the
longer the course of the disease, the greater the rate of
amyloid formation (Figure 1B). The mean rate of amyloid
formation from retina of 30, 60, 90, and 120 dpi and clinical
were 0, 0.06, 0.12, 0.17, and 0.14 hours1, respectively.
PrPSc Immunoreactivity Is Detected in the Retina at
Approximately 60% of Incubation Period
Immunohistochemistry was used to assess PrPSc accumula-
tion in retinal sections from mice at 30, 60, 90, 105, and 120
dpi and at the time clinical illness was observed (Figure 2).
Mock-infected animals (collected at the same time points)
were used as controls. There was no immunostaining for
PrPSc in any of the control animals (Figure 2A). Immuno-
staining was ﬁrst observed at 90 dpi (at approximately 60%
Figure 1 PrPSc seeding activity in the retinas from scrapie-inoculated
mice. Seeding activity is detected at 60 dpi and all subsequent time points.
A: Each trace represents averagedata fromthreebiological samples, each run in
quadruplicate. B:When seeding activity is expressed as amyloid formation rate
(AFR), it demonstrates that amyloid formation is proportional to incubation
period. BH, brain homogenate; BLK, blank well; Neg, negative; Pos, positive.
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of the total incubation period) in multifocal photoreceptor
inner segments throughout the retinal sections of each mouse
examined (Figure 2B). Fifteen days later, at 105 dpi,
immunoreactivity in photoreceptor inner segments was more
widespread, and PrPSc immunoreactivity also was observed
in the outer plexiform (synaptic) layer (Figure 2C). At 120
dpi, PrPSc immunoreactivity was observed in the inner
plexiform layer in addition to the photoreceptor layer and
outer plexiform layer (Figure 2D). At the time of clinical
disease (approximately 153 dpi), PrPSc immunoreactivity
was observed in the inner and outer plexiform layers and in
the photoreceptors that remained (Figure 2E) (although by
this time point, most photoreceptors had been lost).
Activation of Müller Glia Accompanies Early Detection
of PrPSc at 60% of the Incubation Period
Müller glia are radial glial cells that are derived from retinal
progenitor cells.28 Quiescent Müller glia are immunoreactive
for GFAP in their end feet, which are in the optic ﬁber layer.
Under conditions of retinal stress, activated Müller glia have
GFAP immunoreactivity more widely distributed in their
processes that span from the optic ﬁber layer to the outer
limiting membrane.29 Immunohistochemistry with an anti-
body against GFAP was used to assess activation of Müller
glia in retinal sections from 30, 60, 90, 105, and 120 dpi and at
the stage of clinical illness (Figure 3). Mock-inoculated ani-
mals collected at each time point were used as controls. In
control animals, GFAP immunoreactivity was observed in the
optic ﬁber layer (Figure 3A) that contains astrocytes and the
end feet of Müller glia. There was not an appreciable differ-
ence between GFAP immunoreactivity in mock, 30 dpi, or 60
dpi (data not shown). However, GFAP immunoreactivity at 90
dpi was observed in processes of Müller glia that extended as
far as the outer plexiform layer (Figure 3B). At 105 dpi, GFAP
immunoreactivity was more robust, but still only observed
between the optic ﬁber layer and the outer plexiform layer
(Figure 3C). GFAP immunoreactivity at 120 dpi also was
Figure 2 PrPSc immunoreactivity in the retinas from scrapie-inoculated mice. PrPSc immunoreactivity is absent from the retinas of mock-inoculated mice
(A) and all mice examined before 90 dpi. B: At 90 dpi, PrPSc immunoreactivity is observed in occasional photoreceptor inner segments in all mice examined
(arrows). C: By 105 dpi, PrPSc immunoreactivity is consistently observed in photoreceptor inner segments and in the outer plexiform layer. D: A similar but
more widespread distribution is observed at 120 dpi. E: Widespread loss of photoreceptors from the outer nuclear layer (ONL) is observed in the retinas from
mice with clinical disease. In these mice, PrPSc immunoreactivity is observed primarily in the outer plexiform layer (OPL) and inner plexiform layer (IPL). GCL,
ganglion cell layer; INL, inner nuclear layer. Scale bar Z 10 mm (AeE).
Figure 3 Activation of Müller glia in the retinas from scrapie-inoculated mice. A: In the retinas from mock-inoculated animals, glial ﬁbrillary acidic protein
(GFAP) immunoreactivity is observed only in astrocytes and Müller glial end feet in the optic ﬁber layer (OFL). B: GFAP immunoreactivity in other parts of
Müller glia is ﬁrst observed at 90 dpi in the outer plexiform layer (OPL) and occasional processes between the OFL and OPL. GFAP immunoreactivity in Müller
glia increases with incubation period as it becomes more prominent at 105 dpi (C) and 120 dpi (D). E: In the retinas from animals with clinical disease, GFAP-
immunoreactive Müller glia span the entire extent of the retina. GCL, ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; ONL, outer nuclear
layer; OPL, outer plexiform layer. Scale bar Z 10 mm (AeE).
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observed in the outer nuclear layer and reached the outer
limiting membrane in some areas (Figure 3D). At the clinical
stage of disease, there was severe loss of photoreceptors and
Müller glia hypertrophy with GFAP immunoreactivity
observed throughout the thickness of the retina (Figure 3E).
Activation of Microglia Is Detected in the Retina at
70% of Incubation Period
An antibody against CD68 was used to assess activation of
microglia in retinal sections from mice at dpi 30, 60, 90,
105, 120, and the clinical stage of disease in comparison to
mock-inoculated control animals. Rare, multifocal CD68
immunoreactivity was observed in the outer plexiform layer
of control retinal sections (Figure 4A). CD68 immunore-
activity in retinal sections from mice examined at 30 or 60
dpi (data not shown) or 90 dpi (Figure 4B) was not appre-
ciably different from controls. However, at 105 dpi, CD68
immunoreactivity was more intense and widespread in the
outer plexiform layer and also was observed multifocally in
the inner plexiform layer and the optic ﬁber layer
(Figure 4C). Immunoreactivity was further increased at 120
dpi (Figure 4D). In retinal sections from clinically ill mice,
CD68 immunoreactivity was most intense in the optic ﬁber
layer and the inner plexiform layer (Figure 4E). When CD68
immunoreactivity was quantiﬁed at each time point, it
illustrated that the ﬁrst signiﬁcant increase in CD68
immunoreactivity compared to control animals was at the
105 dpi time point (P < 0.05) (Figure 4F) or at approxi-
mately 70% of incubation period.
Neuronal Death Does Not Occur until 80% of
Incubation Period
To determine the time course of photoreceptor loss during
RML scrapie incubation, outer nuclear layer thickness (as
measured by number of photoreceptor cell nuclei) was
assessed at 30, 60, 90, 105, and 120 dpi and in the retinas
from animals with clinical disease (Figure 5). In non-
inoculated control animals and mock-inoculated animals,
the mean outer nuclear layer thickness was 11.05 cell nuclei
(0.81). The mean outer nuclear layer thickness was not
appreciably different from controls at 30, 60, 90, or 105 dpi.
At 120 dpi, however, the average outer nuclear layer
thickness was signiﬁcantly decreased to 8.94 (1.00) cell
nuclei (P < 0.01) and decreased to an average of 2.08
(0.50) cell nuclei thick in retinas from animals with clin-
ical disease. Thus, neuronal death in the form of signiﬁcant
photoreceptor loss (P < 0.01) was not detected in the retinas
until approximately 80% of total incubation period.
Discussion
Prion Seeding Activity Is Detected in the Retina
Relatively Early in Disease Incubation
Our results demonstrate seeding activity by RT-QuIC in the
retina at 60 dpi (approximately 40% of incubation period) in
all samples assayed. Prion seeding activity in the retina was
detected 30 days before the detection of PrPSc via immu-
nohistochemistry. This is consistent with a report that
Figure 4 Activation of microglia in retinas from scrapie-inoculated mice. CD68
immunoreactivity was used to assess microglial activation. CD68 immunoreactivity is
barely detectable in mock-inoculated animals (A) or retinas from animals at 90 dpi
(B). C: There is an observed increase in CD68 immunoreactivity at 105 dpi that is
localized primarily to the outer plexiform layer (OPL). CD68 immunoreactivity in-
creases at 120 dpi (D) and in clinical retinas (E), where it is observed in both the
outer and inner plexiform layers as well as the optic ﬁber layer. F: Quantiﬁcation of
CD68 immunoreactivity illustrates the increase that was ﬁrst detected at 105 dpi, is
greater at 120 dpi, and greatest in retinas from clinically ill animals. Data are
presented as means  SD (F). *P < 0.05, ***P < 0.001, and ****P < 0.0001 versus
mock. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer;
ONL, outer nuclear layer. Scale bar Z 10 mm (AeE).
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compared RT-QuIC with immunohistochemistry and found
RT-QuIC could detect prion seeding activity in tissues that
were negative by immunohistochemistry.30 In the current
study, the next earliest time point was 30 dpi; thus, arrival of
misfolded prion protein was between 30 and 60 dpi.
Because the retina is spatially distinct from the brain, where
the inoculum was delivered, we are conﬁdent that the
seeding activity detected is a result of transport, presumably
retrograde transport via the optic nerve31; however, here we
cannot entirely rule out transport by the circulatory system,
as infectious prion protein was likely in blood of these an-
imals before its detection in retina.32 Rapid retrograde
transport of PrPSc in motor tracts, on the order of 6 weeks,
has been previously reported after inoculation of the sciatic
nerve.33 The consistent appearance of prion seeding activity
in retinas at 60 dpi may suggest widespread distribution,
albeit at a lower level than detected by traditional diagnostic
methods, of misfolded prion protein at a relatively early
stage of the disease process. The time course of some events
(eg, PrPSc immunoreactivity) that we have reported in the
retina is delayed by approximately 30 days compared to
what has been reported in the brains of mice infected with
RML scrapie.34
Accumulation of PrPSc Is Coincident with Activation or
Retinal Glia
We demonstrate detectable accumulation of PrPSc at 90 dpi.
Interestingly, the earliest detectable accumulation of PrPSc
was in the photoreceptor inner segments, rather than in
retinal ganglion cells, whose axons comprise the optic
nerve. Photoreceptors are at least two synaptic contacts
removed from retinal ganglion cells, perhaps suggesting that
accumulation of PrPSc there represents a tropism for mis-
folded protein accumulation in photoreceptors. The earliest
detection of PrPSc accumulation was accompanied by a mild
up-regulation of GFAP in Müller glia. This observation is
consistent with our previous report of speciﬁc Müller glial
activation in regions of early PrPSc accumulation in retinas
of sheep with scrapie.13 Up-regulation of GFAP by Müller
glia is the earliest indicator of retinal stress we have been
able to detect and demonstrates a response by the retinal
tissue to the presence of misfolded prion protein.
Neuronal Loss Does Not Occur until Late in the Disease
Incubation Period
Herein, we report widespread loss of photoreceptors in the
retinas of mice with scrapie. This result is consistent with
other rodent models of TSE, including a hamster model of
transmissible mink encephalopathy35,36 and mouse models
of scrapie37 or Creutzfeldt-Jakob disease.38 Our results
demonstrate, however, that loss of these retinal neurons does
not occur until approximately 80% of the incubation period,
despite the fact that prion-seeding activity was detected in the
retina at 40% of the incubation period. This observation is
Figure 5 Thickness of outer nuclear layer in scrapie-inoculated mice.
Outer nuclear layer (ONL) thickness is expressed as number of cell bodies
spanning the thickness of the layer. Outer nuclear layer thickness is not
different from mock-inoculated controls at 30, 60, 90, or 105 dpi. Outer
nuclear layer thickness decreases in the retinas at 120 dpi and the retinas
from animals with clinical illness. Data are presented as means  SD.
**P < 0.01, ****P < 0.0001 versus control.
Figure 6 Summary of PrPSc transport and scrapie pathogenesis in the mouse retina. The incubation period of RML scrapie in C57Bl/6 mice in this study was
153 days. PrPSc seeding activity was ﬁrst observed at 60 dpi, approximately 40% of the incubation period. PrPSc immunoreactivity and activation of retinal glia
were ﬁrst detected at 90 dpi, which is approximately 60% of the incubation period. At 105 dpi, or approximately 70% of the incubation period, activation of
microglia was detected. Evidence of neuronal death in the outer nuclear layer was not detected until 120 dpi, at approximately 80% of the incubation period of
RML scrapie in C57Bl/6 mice.
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consistent with prior work demonstrating an increase in prion
infectivity before the development of neuropathology.34
Temporal Separation of Key Events in Prion Disease
Our results demonstrate the temporal separation of several
key events in the pathogenesis of prion disease beginning
with the transport of misfolded prion protein from the brain
to the retina (Figure 6). The sequence of events described
herein is not unexpected. However, by determining the time
lag between these events in vivo (eg, the lag between PrPSc
accumulation and cell death), we have provided concrete
criteria that can be used not only to assess the effectiveness
of anti-prion compounds,39 but also to determine the stage
of disease that a given compound would be most effective.
For example, evaluation of an anti-prion compound in mice
infected with RML scrapie between 60 and 90 dpi could
provide information about the ability of the compound to
attenuate accumulation of PrPSc after misfolded prion pro-
tein has been detected in the tissue. Similarly, evaluation of
an immunomodulatory or neuroprotective compound be-
tween 90 and 120 dpi could provide key information about
the relationship between activated microglia and neuronal
death in prion disease.4
The results reported herein contribute to a sizable body of
work describing the time course of prion disease. A great
deal has been done to identify early biomarkers of disease in
cattle,40e42 cervids,43,44 primates,45 sheep,46 and rodent
models of TSEs.34,47 The retina is a tissue that is spatially
separated from the rest of the brain, has a relatively simple
organization, and can be readily assessed using rapid and
noninvasive techniques. This work provides a timeline for
key pathologic milestones of prion disease in the retina and
a model to study mechanisms of disease progression and
evaluate therapeutic interventions.
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